Side-by-side · Research reference
PT-141vsRetatrutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedReviewed13/41 cited
BPhase 2Reviewed10/41 cited
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
Retatrutide
Triple-receptor agonist · Phase 3
SQ · Abdomen · Once weekly
01Mechanism of Action
Parameter
PT-141
Retatrutide
Primary target
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
GLP-1R + GIPR + Glucagon receptor (triple agonism)Jastreboff 2023
Pathway
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Triple-receptor activation → ↑insulin (GLP-1+GIP), ↓gastric emptying, ↑lipid handling, ↑energy expenditure (glucagon component)Jastreboff 2023
Downstream effect
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Maximal weight loss across class. Glucagon component drives lipolysis and energy expenditure beyond GLP-1+GIP aloneJastreboff 2023
Feedback intact?
—
—
Origin
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Synthetic peptide engineered for balanced affinity at three incretin / glucagon receptorsJastreboff 2023
Antibody development
—
—
02Dosage Protocols
Parameter
PT-141
Retatrutide
Standard dose
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
12 mg / week (max efficacy)Jastreboff 2023
Phase 2 trial dose. Phase 3 dosing TBD.
Frequency
PRN, max 8 doses / month
Once weekly
Lower / starter dose
1 mg (off-label)
—
Evidence basis
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Phase 2 trial; Phase 3 ongoingJastreboff 2023
Duration
PRN; reassess if no benefit after 8 doses
Indefinite for chronic indication (presumed)
Reconstitution
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Investigational; not commercially available
Timing
≥45 min before sexual activity
Any time of day
Titration schedule
—
2 mg → 4 mg → 8 mg → 12 mg over 16 weeks
04Side Effects & Safety
Parameter
PT-141
Retatrutide
Flushing
Common, transient
—
Injection site reaction
Erythema, mild pain
—
Headache
Common
—
Hyperpigmentation (focal)
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
—
Hypertension (transient)
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
—
Pregnancy / OB
Contraindicated
Avoid (insufficient data)
Cardiovascular disease
Use caution; transient BP rise
—
Glucose handling
—
Glycemic improvement; rare hyperglycemia from glucagon component
Pancreatitis risk
—
Class warning
Thyroid C-cell tumours
—
Class warning (presumed)
Absolute Contraindications
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Retatrutide
- ·MTC personal or family history (presumed class effect)
- ·Pregnancy / breastfeeding
Relative Contraindications
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
Retatrutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe cardiovascular disease (HR signal)
05Administration Protocol
Parameter
PT-141
Retatrutide
1. Reconstitution
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
Investigational peptide. Research vials reconstituted with bacteriostatic water per label.
2. Injection site
SQ — abdomen or thigh.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
Once weekly, same day.
4. Storage
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
Refrigerate 2–8 °C. Light-protected.
5. Needle
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.
27–31G, 4–8 mm insulin syringe.